Allogene Therapeutics, Inc. (ALLO) is a biotechnology company specializing in the development and commercialization of allogeneic (non-related) CAR-T cell therapies for the treatment of various types of cancer. The company focuses on utilizing genetically modified T cells that can selectively identify and eliminate tumor cells. Allogeneic therapies have the potential to transform the cancer treatment landscape and provide new opportunities for patients. With its research and development of innovative therapeutic approaches, investing in Allogene Therapeutics, Inc. (ALLO) shares may present an interesting investment opportunity for investors interested in the biotechnology and medical sector.